Found: 9
Select item for more details and to access through your institution.
Sequencing antigen‐targeting antibodies and cellular therapies in adults with relapsed/refractory B‐cell acute lymphoblastic leukemia.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 4, p. 666, doi. 10.1002/ajh.26853
- By:
- Publication type:
- Article
Acute patient‐reported outcomes in B‐cell malignancies treated with axicabtagene ciloleucel.
- Published in:
- Cancer Medicine, 2021, v. 10, n. 6, p. 1936, doi. 10.1002/cam4.3664
- By:
- Publication type:
- Article
PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas.
- Published in:
- 2018
- By:
- Publication type:
- journal article
KTE-C19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL): Outcomes in Patients Who Were Treated with Prior Blinatumomab in ZUMA-3.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S184, doi. 10.1016/j.clml.2018.07.015
- By:
- Publication type:
- Article
Response to Boctor and Smith.
- Published in:
- American Journal of Hematology, 2008, v. 83, n. 3, p. 256, doi. 10.1002/ajh.21079
- By:
- Publication type:
- Article
B-Lymphoblastic Leukemia/Lymphoma Associated with t(8;13)(p11;q12)/ZMYM2 (ZNF198)-FGFR1: Rare Case and Review of the Literature.
- Published in:
- Acta Haematologica, 2013, v. 130, n. 3, p. 127, doi. 10.1159/000347030
- By:
- Publication type:
- Article
Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study.
- Published in:
- Journal of Hematology & Oncology, 2022, v. 15, n. 1, p. 1, doi. 10.1186/s13045-022-01379-0
- By:
- Publication type:
- Article
Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Assessment of Clonotypic Rearrangements and Minimal Residual Disease in Lymphoid Malignancies: A Large Cancer Center Experience Using clonoSEQ.
- Published in:
- Archives of Pathology & Laboratory Medicine, 2022, v. 146, n. 4, p. 485, doi. 10.5858/arpa.2020-0457-OA
- By:
- Publication type:
- Article